{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:02:39Z","timestamp":1793646159721,"version":"4.5.1"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2020,8,1]]},"DOI":"10.1001\/jamacardio.2020.0285","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T17:09:09Z","timestamp":1589994549000},"page":"939","source":"Crossref","is-referenced-by-count":38,"title":["Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy"],"prefix":"10.1001","volume":"5","author":[{"given":"Roxana","family":"Mehran","sequence":"first","affiliation":[{"name":"Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Associate Editor, JAMA Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Chandrasekhar","sequence":"additional","affiliation":[{"name":"Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Amsterdam University Medical Center, Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Urban","sequence":"additional","affiliation":[{"name":"H\u00f4pital de la Tour, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Lang","sequence":"additional","affiliation":[{"name":"Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Windhoevel","sequence":"additional","affiliation":[{"name":"Cardiovascular European Research Center, Massy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Spaulding","sequence":"additional","affiliation":[{"name":"European Hospital Georges Pompidou, Assistance Publique H\u00f4pitaux de Paris, Sudden Death Expert Center INSERM U 970, Paris Descartes University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Copt","sequence":"additional","affiliation":[{"name":"Biosensors Europe, Morges, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Stoll","sequence":"additional","affiliation":[{"name":"Biosensors Europe, Morges, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Morice","sequence":"additional","affiliation":[{"name":"Cardiovascular European Research Center, Massy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the LEADERS FREE Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"hoi200010r1","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000523","article-title":"Sex-based differences in outcomes after percutaneous coronary intervention for acute myocardial infarction: a report from TRANSLATE-ACS.","volume":"3","author":"Hess","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"hoi200010r2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/ccd.v85.3","article-title":"Sex-based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: three year results from the HORIZONS-AMI trial.","volume":"85","author":"Yu","year":"2015","journal-title":"Catheter Cardiovasc Interv"},{"issue":"4","key":"hoi200010r3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/ccd.26606","article-title":"Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: results from the PROMETHEUS study.","volume":"89","author":"Chandrasekhar","year":"2017","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"hoi200010r4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/JAHA.116.004319","article-title":"Outcomes of women and men with acute coronary syndrome treated with and without percutaneous coronary revascularization.","volume":"6","author":"Udell","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"hoi200010r5","doi-asserted-by":"publisher","first-page":"773","DOI":"10.4244\/EIJV5I7A130","article-title":"Gender-based issues in interventional cardiology: a consensus statement from the Women in Innovations (WIN) initiative.","volume":"5","author":"Chieffo","year":"2010","journal-title":"EuroIntervention"},{"issue":"12","key":"hoi200010r6","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1001\/jamacardio.2017.3802","article-title":"Outcomes in women and minorities compared with white men 1 year after everolimus-eluting stent implantation: insights and results from the PLATINUM Diversity and PROMUS Element plus post-approval study pooled analysis.","volume":"2","author":"Batchelor","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"7","key":"hoi200010r7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/JAHA.115.001995","article-title":"Trends in gender differences in cardiac care and outcome after acute myocardial infarction in Western Sweden: a report from the Swedish Web System for Enhancement of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART).","volume":"4","author":"Redfors","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"hoi200010r8","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1161\/CIRCULATIONAHA.116.024406","article-title":"Race and sex differences in post-myocardial infarction angina frequency and risk of 1-year unplanned rehospitalization.","volume":"135","author":"Hess","year":"2017","journal-title":"Circulation"},{"issue":"10","key":"hoi200010r9","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.jacc.2010.06.008","article-title":"Coronary stents: looking forward.","volume":"56","author":"Garg","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"hoi200010r10","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1161\/CIRCULATIONAHA.114.012658","article-title":"Hypersensitivity reaction in the US Food and Drug Administration-approved second-generation drug-eluting stents: histopathological assessment with ex vivo optical coherence tomography.","volume":"131","author":"Otsuka","year":"2015","journal-title":"Circulation"},{"issue":"2","key":"hoi200010r11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1161\/CIRCULATIONAHA.113.001790","article-title":"Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans.","volume":"129","author":"Otsuka","year":"2014","journal-title":"Circulation"},{"issue":"21","key":"hoi200010r12","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk.","volume":"373","author":"Urban","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"hoi200010r13","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.4244\/EIJ-D-17-00720","article-title":"Two-year outcomes of high bleeding risk patients with acute coronary syndrome after Biolimus A9 polymer-free drug-coated stents: a LEADERS FREE substudy.","volume":"13","author":"Jensen","year":"2018","journal-title":"EuroIntervention"},{"issue":"2","key":"hoi200010r14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jacc.2016.10.009","article-title":"2-Year outcomes of high bleeding risk patients after polymer-free drug-coated stents.","volume":"69","author":"Garot","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"hoi200010r15","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third universal definition of myocardial infarction.","volume":"60","author":"Thygesen","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"hoi200010r16","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions.","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"issue":"23","key":"hoi200010r17","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"hoi200010r18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1161\/CIRCINTERVENTIONS.116.003577","article-title":"Sex differences in the clinical impact of high platelet reactivity after percutaneous coronary intervention with drug-eluting stents: results from the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).","volume":"10","author":"Yu","year":"2017","journal-title":"Circ Cardiovasc Interv"},{"issue":"14","key":"hoi200010r19","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jcin.2016.04.004","article-title":"Sex-based differences in cessation of dual-antiplatelet therapy following percutaneous coronary intervention with stents.","volume":"9","author":"Yu","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"10","key":"hoi200010r20","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jacc.2010.06.007","article-title":"Coronary stents: current status.","volume":"56","author":"Garg","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"hoi200010r21","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1161\/CIRCULATIONAHA.106.666826","article-title":"Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? late stent thrombosis: a nuisance in both bare metal and drug-eluting stents.","volume":"115","author":"Serruys","year":"2007","journal-title":"Circulation"},{"issue":"6","key":"hoi200010r22","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jcin.2011.02.011","article-title":"Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events), ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy), and HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trials.","volume":"4","author":"Mehran","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"issue":"11","key":"hoi200010r23","first-page":"69","article-title":"Effect of thrombotic and bleeding risk according to platelet reactivity on 2-year mortality: the ADAPT-DES study.","author":"Chandrasekhar","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"hoi200010r24","first-page":"72","article-title":"Validation of PARIS risk scores in patients treated with everolimus-eluting stents for left main coronary artery disease: analysis from the EXCEL Trial.","author":"Sorrentino","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"hoi200010r25","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jcmg.2012.02.003","article-title":"Gender and the extent of coronary atherosclerosis, plaque composition, and clinical outcomes in acute coronary syndromes.","volume":"5","author":"Lansky","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"issue":"8","key":"hoi200010r26","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jcin.2014.04.007","article-title":"A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial.","volume":"7","author":"Rao","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"issue":"23","key":"hoi200010r27","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"issue":"10060","key":"hoi200010r28","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1016\/S0140-6736(16)31920-1","article-title":"Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.","volume":"388","author":"von Birgelen","year":"2016","journal-title":"Lancet"},{"issue":"29","key":"hoi200010r29","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1093\/eurheartj\/ehu026","article-title":"Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.","volume":"35","author":"Silber","year":"2014","journal-title":"Eur Heart J"},{"issue":"5","key":"hoi200010r30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/CIRCINTERVENTIONS.114.001362","article-title":"Stent thrombosis and dual antiplatelet therapy interruption with everolimus-eluting stents: insights from the Xience V Coronary Stent System Trials.","volume":"8","author":"G\u00e9n\u00e9reux","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"issue":"10115","key":"hoi200010r31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(17)32713-7","article-title":"Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial.","volume":"391","author":"Varenne","year":"2018","journal-title":"Lancet"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2766284\/jamacardiology_mehran_2020_oi_200010_1597695810.39277.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T15:29:14Z","timestamp":1597850954000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2766284"}},"subtitle":["A Secondary Analysis of the LEADERS FREE Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,8,1]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2020.0285","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,1]]}}}